Neurosteroids and epileptogenesis

Journal of Neuroendocrinology

Volumn 25, Issue 11, 2013, Pages 980-990

  Biagini, G ^a   Rustichelli, C ^a   Curia, G ^a   Vinet, J ^a   Lucchi, C ^a   Pugnaghi, M ^a   Meletti, S ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Allopregnanolone; Epilepsy; Glia; Hippocampus; Neurosteroids; Pilocarpine

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; 4 AMINOBUTYRIC ACID A RECEPTOR; BENZODIAZEPINE RECEPTOR; CARBAMAZEPINE; CHEMOKINE RECEPTOR CXCR4; CHOLESTEROL MONOOXYGENASE (SIDE CHAIN CLEAVING); ESTRADIOL; FINASTERIDE; GONADOTROPIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LAMOTRIGINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MINOCYCLINE; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUROSTEROID; PILOCARPINE; PROGESTERONE; STEROID 5ALPHA REDUCTASE; TUMOR NECROSIS FACTOR ALPHA; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS;

ADD ON THERAPY; ASTROCYTE; CATAMENIAL EPILEPSY; CELL ACTIVATION; DISEASE DURATION; DRUG WITHDRAWAL; ELECTROENCEPHALOGRAM; ENZYME INHIBITION; EPILEPTIC STATE; EPILEPTOGENESIS; GLIA CELL; HUMAN; IMMUNOREACTIVITY; LATENT PERIOD; MICROGLIA; NERVE CELL EXCITABILITY; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; SEIZURE; TEMPORAL LOBE EPILEPSY; ANIMAL; BRAIN; ENZYMOLOGY; EPILEPSY; GLIA; IMMUNOLOGY; METABOLISM; PATHOPHYSIOLOGY; RAT;

ANIMALS; BRAIN; EPILEPSY; HUMANS; NEUROGLIA; NEUROTRANSMITTER AGENTS; RATS;

EID: 84886714701     PISSN: 09538194     EISSN: 13652826     Source Type: Journal    
DOI: 10.1111/jne.12063     Document Type: Review

References (87)

1. Strzelczyk A, Reese JP, Dodel R, Hamer HM. Cost of epilepsy: a systematic review. Pharmacoeconomics 2008; 26: 463-476.
2. Téllez-Zenteno JF, Hernández-Ronquillo L. A review of the epidemiology of temporal lobe epilepsy. Epilepsy Res Treat 2012; 2012: 630853.
3. Mathern GW, Adelson PD, Cahan LD, Leite JP. Hippocampal neuron damage in human epilepsy: Meyer's hypothesis revisited. Prog Brain Res 2002; 135: 237-251.
4. Curia G, Longo D, Biagini G, Jones RS, Avoli M. The pilocarpine model of temporal lobe epilepsy. J Neurosci Methods 2008; 172: 143-157.
5. Bartolomei F, Chauvel P, Wendling F. Spatio-temporal dynamics of neuronal networks on partial epilepsy. Rev Neurol (Paris) 2005; 161: 767-780.
6. Morimoto K, Fahnestock M, Racine RJ. Kindling and status epilepticus models of epilepsy: rewiring the brain. Prog Neurobiol 2004; 73: 1-60.
7. Lothman EW, Bertram EH, Bekenstein JW, Perlin JB. Self-sustaining limbic status epilepticus induced by 'continuous' hippocampal stimulation: electrographic and behavioral characteristics. Epilepsy Res 1989; 3: 107-119.
8. Ben-Ari Y, Cossart R. Kainate, a double agent that generates seizures: two decades of progress. Trends Neurosci 2000; 23: 580-587.
9. Gualtieri F, Curia G, Marinelli C, Biagini G. Increased perivascular laminin predicts damage to astrocytes in CA3 and piriform cortex following chemoconvulsive treatments. Neuroscience 2012; 218: 278-294.
10. Turski WA, Cavalheiro EA, Schwarz M, Czuczwar SJ, Kleinrok Z, Turski L. Limbic seizures produced by pilocarpine in rats: behavioural, electroencephalographic and neuropathological study. Behav Brain Res 1983; 9: 315-335.
11. Covolan L, Mello LE. Temporal profile of neuronal injury following pilocarpine or kainic acid-induced status epilepticus. Epilepsy Res 2000; 39: 133-152.
12. Leite JP, Garcia-Cairasco N, Cavalheiro EA. New insights from the use of pilocarpine and kainate models. Epilepsy Res 2002; 50: 93-103.
13. Tang FR, Loke WK, Ling EA. Comparison of status epilepticus models induced by pilocarpine and nerve agents - a systematic review of the underlying aetiology and adopted therapeutic approaches. Curr Med Chem 2011; 18: 888-899.
14. Potschka H. Animal models of drug-resistant epilepsy. Epileptic Disord 2012; 14: 226-234.
15. Avoli M, D'Antuono M, Louvel J, Köhling R, Biagini G, Pumain R, D'Arcangelo G, Tancredi V. Network and pharmacological mechanisms leading to epileptiform synchronization in the limbic system in vitro. Prog Neurobiol 2002; 68: 167-207.
16. Sutula T. Seizure-induced axonal sprouting: assessing connections between injury, local circuits, and epileptogenesis. Epilepsy Curr 2002; 2: 86-91.
17. Gualtieri F, Marinelli C, Longo D, Pugnaghi M, Nichelli PF, Meletti S, Biagini G. Hypoxia markers are expressed in interneurons exposed to recurrent seizures. Neuromolecular Med 2013; 15: 133-146.
18. Scharfman HE, McCloskey DP. Postnatal neurogenesis as a therapeutic target in temporal lobe epilepsy. Epilepsy Res 2009; 85: 150-161.
19. Wieser HG. ILAE Commission on Neurosurgery of Epilepsy. ILAE Commission Report. Mesial temporal lobe epilepsy with hippocampal sclerosis. Epilepsia 2004; 45: 695-714.
20. Glien M, Brandt C, Potschka H, Löscher W. Effects of the novel antiepileptic drug levetiracetam on spontaneous recurrent seizures in the rat pilocarpine model of temporal lobe epilepsy. Epilepsia 2002; 43: 350-357.
21. Chakir A, Fabene PF, Ouazzani R, Bentivoglio M. Drug resistance and hippocampal damage after delayed treatment of pilocarpine-induced epilepsy in the rat. Brain Res Bull 2006; 71: 127-138.
22. Dalby NO, Mody I. The process of epileptogenesis: a pathophysiological approach. Curr Opin Neurol 2001; 14: 187-192.
23. Pitkänen A, Lukasiuk K. Mechanisms of epileptogenesis and potential treatment targets. Lancet Neurol 2011; 10: 173-186.
24. Biagini G, Baldelli E, Longo D, Pradelli L, Zini I, Rogawski MA, Avoli M. Endogenous neurosteroids modulate epileptogenesis in a model of temporal lobe epilepsy. Exp Neurol 2006; 201: 519-524.
25. Biagini G, Longo D, Baldelli E, Zoli M, Rogawski MA, Bertazzoni G, Avoli M. Neurosteroids and epileptogenesis in the pilocarpine model: evidence for a relationship between P450scc induction and length of the latent period. Epilepsia 2009; 50(Suppl. 1): 53-58.
26. Biagini G, Panuccio G, Avoli M. Neurosteroids and epilepsy. Curr Opin Neurol 2010; 23: 170-176.
27. Biagini G, Marinelli C, Panuccio G, Puia G, Avoli M. Glia-neuron interactions: neurosteroids and epileptogenesis. In: Noebels JL, Avoli M, Rogawski M, Olsen R, Delgado-Escueta AV, eds. Jasper's Basic Mechanisms of the Epilepsies - 4th Edition, Contemporary Neurology Series. 80. New York, NY: Oxford University Press, 2012: 635-647.
28. Löscher W, Brandt C. Prevention or modification of epileptogenesis after brain insults: experimental approaches and translational research. Pharmacol Rev 2010; 62: 668-700.
29. D'Ambrosio R, Hakimian S, Stewart T, Verley DR, Fender JS, Eastman CL, Sheerin AH, Gupta P, Diaz-Arrastia R, Ojemann J, Miller JW. Functional definition of seizure provides new insight into post-traumatic epileptogenesis. Brain 2009; 132: 2805-2821.
30. Walker MC, White HS, Sander JW. Disease modification in partial epilepsy. Brain 2002; 125: 1937-1950.
31. A receptor α1 subunit levels in hippocampal dentate gyrus inhibits epilepsy development in an animal model of temporal lobe epilepsy. J Neurosci 2006; 26: 11342-11346.
32. Bortel A, Lévesque M, Biagini G, Gotman J, Avoli M. Convulsive status epilepticus duration as determinant for epileptogenesis and interictal discharge generation in the rat limbic system. Neurobiol Dis 2010; 40: 478-489.
33. Goffin K, Nissinen J, Van Laere K, Pitkänen A. Cyclicity of spontaneous recurrent seizures in pilocarpine model of temporal lobe epilepsy in rat. Exp Neurol 2007; 205: 501-505.
34. Jung S, Jones TD, Lugo JN Jr, Sheerin AH, Miller JW, D'Ambrosio R, Anderson AE, Poolos NP. Progressive dendritic HCN channelopathy during epileptogenesis in the rat pilocarpine model of epilepsy. J Neurosci 2007; 27: 13012-13021.
35. Williams PA, White AM, Clark S, Ferraro DJ, Swiercz W, Staley KJ, Dudek FE. Development of spontaneous recurrent seizures after kainate-induced status epilepticus. J Neurosci 2009; 29: 2103-2112.
36. Ben-Ari Y, Dudek FE. Primary and secondary mechanisms of epileptogenesis in the temporal lobe: there is a before and an after. Epilepsy Curr 2010; 10: 118-125.
37. van Vliet EA, Aronica E, Tolner EA, Lopes da Silva FH, Gorter JA. Progression of temporal lobe epilepsy in the rat is associated with immunocytochemical changes in inhibitory interneurons in specific regions of the hippocampal formation. Exp Neurol 2004; 187: 367-379.
38. Fabene PF, Navarro Mora G, Martinello M, Rossi B, Merigo F, Ottoboni L, Bach S, Angiari S, Benati D, Chakir A, Zanetti L, Schio F, Osculati A, Marzola P, Nicolato E, Homeister JW, Xia L, Lowe JB, McEver RP, Osculati F, Sbarbati A, Butcher EC, Constantin G. A role for leukocyte-endothelial adhesion mechanisms in epilepsy. Nat Med 2008; 14: 1377-1383.
39. Vezzani A, French J, Bartfai T, Baram TZ. The role of inflammation in epilepsy. Nat Rev Neurol 2011; 7: 31-40.
40. Kovács R, Heinemann U, Steinhäuser C. Mechanisms underlying blood-brain barrier dysfunction in brain pathology and epileptogenesis: role of astroglia. Epilepsia 2012; 53(Suppl. 6): 53-59.
41. Losi G, Cammarota M, Carmignoto G. The role of astroglia in the epileptic brain. Front Pharmacol 2012; 3: 132.
42. Olah M, Biber K, Vinet J, Boddeke HW. Microglia phenotype diversity. CNS Neurol Disord Drug Targets 2011; 10: 108-118.
43. Vinet J, Weering HR, Heinrich A, Kälin RE, Wegner A, Brouwer N, Heppner FL, Rooijen NV, Boddeke HW, Biber K. Neuroprotective function for ramified microglia in hippocampal excitotoxicity. J Neuroinflammation 2012; 9: 27.
44. Fabene PF, Bramanti P, Constantin G. The emerging role for chemokines in epilepsy. J Neuroimmunol 2010; 224: 22-27.
45. Abraham J, Fox PD, Condello C, Bartolini A, Koh S. Minocycline attenuates microglia activation and blocks the long-term epileptogenic effects of early-life seizures. Neurobiol Dis 2012; 46: 425-430.
46. Gandhi R, Laroni A, Weiner HL. Role of the innate immune system in the pathogenesis of multiple sclerosis. J Neuroimmunol 2010; 221: 7-14.
47. Wee YV. Inflammation in neurological disorders: a help or a hindrance? Neuroscientist 2010; 16: 408-420.
48. Almolda B, González B, Castellano B. Activated microglial cells acquire an immature dendritic cell phenotype and may terminate the immune response in an acute model of EAE. J Neuroimmunol 2010; 223: 39-54.
49. Penkowa M, Molinero A, Carrasco J, Hidalgo J. Interleukin-6 deficiency reduces the brain inflammatory response and increases oxidative stress and neurodegeneration after kainic acid-induced seizures. Neuroscience 2001; 102: 805-818.
50. Mirrione MM, Konomos DK, Gravanis I, Dewey SL, Aguzzi A, Heppner FL, Tsirka SE. Microglial ablation and lipopolysaccharide preconditioning affects pilocarpine-induced seizures in mice. Neurobiol Dis 2010; 39: 85-97.
51. Corpéchot C, Robel P, Axelson M, Sjövall J, Baulieu EE. Characterization and measurement of dehydroepiandrosterone sulfate in rat brain. Proc Natl Acad Sci USA 1981; 78: 4704-4707.
52. Le Goascogne C, Robel P, Gouézou M, Sananès N, Baulieu EE, Waterman M. Neurosteroids: cytochrome P-450scc in rat brain. Science 1987; 237: 1212-1215.
53. Ukena K, Usui M, Kohchi C, Tsutsui K. Cytochrome P450 side-chain cleavage enzyme in the cerebellar Purkinje neuron and its neonatal change in rats. Endocrinology 1998; 139: 137-147.
54. Shibuya K, Takata N, Hojo Y, Furukawa A, Yasumatsu N, Kimoto T, Enami T, Suzuki K, Tanabe N, Ishii H, Mukai H, Takahashi T, Hattori TA, Kawato S. Hippocampal cytochrome P450s synthesize brain neurosteroids which are paracrine neuromodulators of synaptic signal transduction. Biochim Biophys Acta 2003; 1619: 301-316.
55. Zwain IH, Yen SS. Neurosteroidogenesis in astrocytes, oligodendrocytes, and neurons of cerebral cortex of rat brain. Endocrinology 1999; 140: 3843-3852.
56. Stephenson DT, Schober DA, Smalstig EB, Mincy RE, Gehlert DR, Clemens JA. Peripheral benzodiazepine receptors are colocalized with activated microglia following transient global forebrain ischemia in the rat. J Neurosci 1995; 15: 5263-5274.
57. 3H]PK11195 binding to activated microglia. J Neurocytol 1997; 26: 77-82.
58. Kuhlmann AC, Guilarte TR. Cellular and subcellular localization of peripheral benzodiazepine receptors after trimethyltin neurotoxicity. J Neurochem 2000; 74: 1694-1704.
59. 3H]PK11195 binding in gerbil hippocampus after transient forebrain ischemia. J Neurosci Res 2001; 64: 493-500.
60. SCC (CYP XIA1), and 3βhydroxysteroid dehydrogenase in the rat brain. J Neurochem 1998; 71: 2231-2238.
61. Sierra A. Neurosteroids: the StAR protein in the brain. J Neuroendocrinol 2004; 16: 787-793.
62. Papadopoulos V, Baraldi M, Guilarte TR, Knudsen TB, Lacapère JJ, Lindemann P, Norenberg MD, Nutt D, Weizman A, Zhang MR, Gavish M. Translocator protein (18 kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol Sci 2006; 27: 402-409.
63. Biagini G, Baldelli E, Longo D, Contri MB, Guerrini U, Sironi L, Gelosa P, Zini I, Ragsdale DS, Avoli M. Proepileptic influence of a focal vascular lesion affecting entorhinal cortex-CA3 connections after status epilepticus. J Neuropathol Exp Neurol 2008; 67: 687-701.
64. Racine RJ. Modification of seizure activity by electrical stimulation: II. Motor seizure. Electroencephalogr Clin Neurophysiol 1972; 32: 281-294.
65. A receptor. Nat Rev Neurosci 2005; 6: 565-575.
66. Mukai Y, Higashi T, Nagura Y, Shimada K. Studies on neurosteroids XXV. Influence of a 5α-reductase inhibitor, finasteride, on rat brain neurosteroid levels and metabolism. Biol Pharm Bull 2008; 31: 1646-1650.
67. Concas A, Mostallino MC, Porcu P, Follesa P, Barbaccia ML, Trabucchi M, Purdy RH, Grisenti P, Biggio G. Role of brain allopregnanolone in the plasticity of γ-aminobutyric acid type A receptor in rat brain during pregnancy and after delivery. Proc Natl Acad Sci USA 1998; 95: 13284-13289.
68. Rustichelli C, Pinetti D, Lucchi C, Ravazzini F, Puia G. Simultaneous determination of pregnenolone sulphate, dehydroepiandrosterone and allopregnanolone in rat brain areas by liquid chromatography-electrospray tandem mass spectrometry. J Chromatogr B 2013; 930: 62-69.
69. Reddy DS. Neuroendocrine aspects of catamenial epilepsy. Horm Behav 2013; 63: 254-266.
70. A receptors mediating tonic inhibition alter seizure susceptibility and anxiety. Nat Neurosci 2005; 8: 797-804.
71. Guille C, Spencer S, Cavus I, Epperson CN. The role of sex steroids in catamenial epilepsy and premenstrual dysphoric disorder: implications for diagnosis and treatment. Epilepsy Behav 2008; 13: 12-24.
72. A receptor gene regulation in the brain and anxiety behavior. Steroids 2002; 67: 519-528.
73. Bäckström T, Andersson A, Andreé L, Birzniece V, Bixo M, Björn I, Haage D, Isaksson M, Johansson IM, Lindblad C, Lundgren P, Nyberg S, Odmark IS, Strömberg J, Sundström-Poromaa I, Turkmen S, Wahlström G, Wang M, Wihlbäck AC, Zhu D, Zingmark E. Pathogenesis of menstrual cycle-linked CNS disorders. Ann NY Acad Sci 2003; 1007: 42-53.
74. Selye H. On the hormonal activity of a steroid compound. Science 1941; 94: 94.
75. Reddy DS, Castaneda DC, O'Malley BW, Rogawski MA. Anticonvulsant activity of progesterone and neurosteroids in progesterone receptor knockout mice. J Pharmacol Exp Ther 2004; 310: 230-239.
76. Kokate TG, Banks MK, Magee T, Yamaguchi S, Rogawski MA. Finasteride, a 5α-reductase inhibitor, blocks the anticonvulsant activity of progesterone in mice. J Pharmacol Exp Ther 1999; 288: 679-684.
77. Frye CA, Rhodes ME, Walf A, Harney J. Progesterone reduces pentylenetetrazol-induced ictal activity of wild type mice but not those deficient in type I 5α-reductase. Epilepsia 2002; 43(Suppl. 5): 14-17.
78. Herzog AG. Hormonal therapies: progesterone. Neurotherapeutics 2009; 6: 383-391.
79. Reddy DS, Kim HY, Rogawski MA. Neurosteroid withdrawal model of perimenstrual catamenial epilepsy. Epilepsia 2001; 42: 328-336.
80. Reddy DS, Rogawski MA. Neurosteroid replacement therapy for catamenial epilepsy. Neurotherapeutics 2009; 6: 392-401.
81. Reddy DS. The role of neurosteroids in the pathophysiology and treatment of catamenial epilepsy. Epilepsy Res 2009; 85: 1-30.
82. Lawrence C, Martin BS, Sun C, Williamson J, Kapur J. Endogenous neurosteroid synthesis modulates seizure frequency. Ann Neurol 2010; 67: 689-693.
83. Taubøll E, Lundervold A, Gjerstad L. Temporal distribution of seizures in epilepsy. Epilepsy Res 1991; 8: 153-165.
84. Herzog AG. Progesterone therapy in women with complex partial and secondary generalized seizures. Neurology 1995; 45: 1660-1662.
85. Herzog AG, Frye CA. Seizure exacerbation associated with inhibition of progesterone metabolism. Ann Neurol 2003; 53: 390-391.
86. Mani SK, Oyola MG. Progesterone signaling mechanisms in brain and behavior. Front Endocrinol 2012; 3: 7.
87. Pugnaghi M, Monti G, Biagini G, Meletti S. Temporal lobe epilepsy exacerbation during pharmacological inhibition of endogenous neurosteroid synthesis. BMJ Case Rep 2013; pii: bcr2012008204.